These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942 [TBL] [Abstract][Full Text] [Related]
64. Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa. Pitso L; Potgieter S; Van der Spoel van Dijk A S Afr Med J; 2019 Aug; 109(9):659-664. PubMed ID: 31635590 [TBL] [Abstract][Full Text] [Related]
65. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Tiberi S; Payen MC; Sotgiu G; D'Ambrosio L; Alarcon Guizado V; Alffenaar JW; Abdo Arbex M; Caminero JA; Centis R; De Lorenzo S; Gaga M; Gualano G; Roby Arias AJ; Scardigli A; Skrahina A; Solovic I; Sulis G; Tadolini M; Akkerman OW; Alarcon Arrascue E; Aleska A; Avchinko V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB Eur Respir J; 2016 Apr; 47(4):1235-43. PubMed ID: 26965290 [TBL] [Abstract][Full Text] [Related]
66. A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea. Shim TS; Pai H; Mok J; Lee SH; Kwon YS; Choi JC; Park J; Birmingham E; Mao G; Alquier L; Davis K; Thoret-Bauchet F; Kim JH; Kim H; Bakare N BMC Infect Dis; 2023 Jan; 23(1):15. PubMed ID: 36624432 [TBL] [Abstract][Full Text] [Related]
68. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Chahine EB; Karaoui LR; Mansour H Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600 [TBL] [Abstract][Full Text] [Related]
69. Strengthened capacity of India´s bedaquiline Conditional Access Programme for introducing new drugs and regimens. Sachdeva KS; Arora N; Solanki R; Singla R; Sarin R; Bhatnagar A; Khanna A; Atahavale A; Shridhar R; Barua SR; Parmar M; Farooq SI; Ramachandran R; Alavadi U; Swamickan R; Tonsing J; Patel Y; Singla N Int J Tuberc Lung Dis; 2020 Oct; 24(10):1067-1072. PubMed ID: 33126941 [No Abstract] [Full Text] [Related]
70. Bedaquiline in Drug-Resistant Tuberculosis: A Mini-Review. Singh B; Singh C Curr Mol Pharmacol; 2023; 16(3):243-253. PubMed ID: 36919348 [TBL] [Abstract][Full Text] [Related]
71. ▼Bedaquiline for multidrug-resistant tuberculosis. Drug Ther Bull; 2014 Nov; 52(11):129-32. PubMed ID: 25395481 [TBL] [Abstract][Full Text] [Related]
72. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. Chesov D; Heyckendorf J; Alexandru S; Donica A; Chesov E; Reimann M; Crudu V; Botnaru V; Lange C Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33334942 [TBL] [Abstract][Full Text] [Related]
73. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. Kunkel A; Cobelens FG; Cohen T PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274 [TBL] [Abstract][Full Text] [Related]
74. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates. Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332 [TBL] [Abstract][Full Text] [Related]
75. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing. Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132 [TBL] [Abstract][Full Text] [Related]
76. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis. Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889 [TBL] [Abstract][Full Text] [Related]
77. Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis. Tack I; Dumicho A; Ohler L; Shigayeva A; Bulti AB; White K; Mbatha M; Furin J; Isaakidis P Clin Infect Dis; 2021 Nov; 73(9):e3563-e3571. PubMed ID: 33372989 [TBL] [Abstract][Full Text] [Related]
79. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149 [TBL] [Abstract][Full Text] [Related]
80. Successful treatment of XDR-TB patient in Tanzania: report of the first XDR-TB patient. Lyakurwa D; Lyimo J; Mleoh L; Riziki K; Lupinda M; Mpondo BC Trop Doct; 2019 Jul; 49(3):224-226. PubMed ID: 30885056 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]